Anti-Human HLA-DQ (MHC Class II) – PE

This R-phycoerythrin (R-PE) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

This R-PE conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Blue Laser (488 nm) and/or Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Clone 1a3 recognizes a monomorphic epitope on human HLA-DQ1. It does not cross-react with HLA-DR or HLA-DP.

HLA-DQ antibody, clone 1a3, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DQ isotype (HLA-DQ). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation². HLA-DQ consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain³ encoded by the HLA-DQA1 and HLA-DQB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens⁴. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling⁵. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation⁶ and can transduce signals into T cells, enhancing T cell proliferation and activity⁷. Specific alleles of HLA-DQ are associated with autoimmune diseases, including celiac disease⁸ and type 1 diabetes⁹, and graft-versus-host disease¹⁰.

HLA-DQ is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.

CD3/TCR, CD8

1. Shookster L, et al. (1987) Hum Immunol. 20(1):59-70
2. Holling TM, Schooten E, van Den Elsen PJ. (2004) Hum Immunol. 65(4):282-90
3. Mitaksov V, Fremont DH. (2006) J Biol Chem. 281(15):10618-25
4. Wieczorek M, et al. (2017) Front Immunol. 8:292
5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921
6. Barnaba V, et al (1994) Eur J Immunol. 24(1):71-5
7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60
8. Castaño L, et al. (2004) J Pediatr Gastroenterol Nutr. 39:80–84
9. Cucca F, et al. (1993) Hum Immunol. 37:85 –94
10. Petersdorf EW, (1996) Proc Natl Acad Sci USA. 93(26):15358-63